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[57] ABSTRACT 
Biotinylated isocoumarins, their use in inhibiting serine 
proteases with chymotrypsin-like and elastase-like spec-
ificity and in purifying proteins. 
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BIOTINYLATED ISOCOUMARINS 
BACKGROUND OF THE INVENTION 
extensive secondary specificity and recognize amino 
acid residues removed from the P1 residue. 
1. Field of the Invention 
This invention relates to a novel class of heterocyclic 
compounds useful for selectively inhibiting chymotryp-
sin-like enzymes, selectively inhibiting clastase or for 
generally inhibiting serine proteases of many classes. 
We have found that isocoumarins substituted with bio- lO 
tin and hydrophobic groups arc potent inhibitors of 
chymases, elastascs, and other serine proteases. These 
biotinylatcd isocoumarins can be used to selectively or 
generally remove proteases from solution or biological 
systems. They can be used either selectively or gener- lS 
ally to isolate serine proteases. They can also be used to 
selectively or generally inhibit serine proteases either in 
vitro or in biological systems. 
It is an object of this invention to discover new bi-
otinylated protease inhibitors, especially elastase inhibi-
S tors, and chymase inhibitors. These inhibitors are useful 
for controlling tissue damage and various inflammatory 
conditions mediated by proteases particularly elastases. 
The inhibitors of this invention would also be useful for 
2. Description of the Related Art 
Serine proteases play critical roles in several physio- 20 
logical processes such as digestion, blood coagulation, 
complement activation, fibrinolysis, viral infection, fer-
tilization, and reproduction. Serine proteases are not 
only a physiological necessity, but also a potential ha-
zard if they are not controlled. Uncontrolled proteolysis 25 
by elastascs may cause pancreatitis, emphysema, rheu-
matoid arthritis, bronchial inflammation and adult respi-
ratory distress syndrome. Human polymorphonuclear 
leukocyte elastase may also be involved in blistering. 
Accordingly, specific and selective inhibitors of these 30 
proteases should be potent anti-inflammatory agents 
useful in the treatment of protease-related diseases 
(Powers and Harper, in Proteinase Inhibitors, Barrett 
and Salvesen, eds., Elsevier, 1986, pp 55-152, incorpo-
rated herein by reference). In vitro proteolysis by chy- 3S 
motrypsin or the elastase family is a serious problem in 
the production, purification, isolation, transport or stor-
age of peptides and proteins. It is often desirable to 
remove all proteases from solution or biological sys-
tems. In other cases, it is desirable to isolate or remove 40 
a specific serine protease. 
controlling hormone processing by serine proteases and 
for treating diseases related to tryptases and chymases 
such as inflammation and skin blistering. 
It is a further object of this invention to find a novel 
group of specific biotinylated inhibitors useful in vitro 
for inhibiting trypsin, elastase, chymotrypsin and other 
serine proteases of similar specificity and for inhibiting 
serine proteases in general. Such inhibitors could be 
used to identify and isolate new proteolytic enzymes 
encountered in research. They could also be used in 
research and industrially to prevent undesired proteoly-
sis that occurs during the production, isolation, purifica-
tion, transport and storage of valuable peptides and 
proteins. Such proteolysis often destroys or alters the 
activity and/or function of the peptides and proteins. 
Uses would include the addition of the inhibitors to 
antibodies, enzymes, plasma proteins, tissue extracts or 
other proteins and peptides which are widely sold for 
use in clinical analyses, biomedical research, and for 
many other reasons. For some uses a specific inhibitor 
would be desirable, while in other cases, an inhibitor 
with general specificity would be preferred. The bi-
otinylated inhibitors could also be used to remove pro-
teases, isolate serine proteases from solution or biologi-
cal systems, or to detect proteases in solution or in bio-
logical systems by utilizing the affinity or biotin for 
avidin either on columns or in solution. Numerous avi-
din derivatives containing enzymes, heavy metal mark-
ers, antigens, or antibodies are commercially available 
which could be use to react with serine protease con-
taining a biotinylate inhibitory moiety covalently at-
tached to the protease. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Isocoumarins substituted with hydrophobic groups 
have been found to be excellent inhibitors of several 
serine proteases including human leukocyte clastase, 
Anti-inflammatory agents are used to treat elastases-
associated inflammation including rheumatoid arthritis 
and emphysema. Although the naturally occurring pro-
tease inhibitor, al-protease inhibitor (al-Pl) has been 4S 
used to treat patients with emphysema, this inhibitor is 
not widely used clinically due to the high dosage 
needed for the treatment and difficulty of producing 
large quantities. Therefore small molecular weight elas-
tase inhibitors are needed for therapy. so porcine pancreatic elastase, bovine chymotrypsin and 
human leukocyte cathespsin G. These compounds in-
hibit the serine proteases by reaction with the active site 
serine to form an acyl enzyme, which in some cases may 
SUMMARY OF THE INVENTION 
It is an object of this invention to find a novel group 
of specific biotinylatcd inhibitors for elastasc, chymo-
trypsin and other serine proteases of similar substrate SS 
specificity and for serine proteases in general. Inhibitors 
are compounds that reduce or eliminate the catalytic 
activity of the enzyme. Trypsin and trypsin-like en-
zymes normally cleave peptide bonds in proteins and 
peptides where the amino acid residue on the carbonyl 60 
side of the split bond (Pt residue) is Lys or Arg. Elastase 
and clastasc-like enzymes, on the other hand, cleave 
peptide bonds where the Pt amino acid is Ala, Val, Ser, 
Leu and other similar amino ai::ids. Chymotrypsin and 
chymotrypsin-like enzymes hydrolyze peptide bonds 6S 
where Pt amino acid is Trp, Tyr, Phe, Met, Leu or 
other amino acid residues which contain aromatic or 
large alkyl side chains. All of the above enzymes have 
further react with another active site nuclcophile to 
form an additional covalent bond. These structures may 
be used in vivo to treat diseases such as emphysema, 
adult respiratory distress syndrome, rheumatoid arthri-
tis and pancreatitis which result from uncontrolled pro-
teolysis by elastase, chymotrypsin, trypsin and related 
serine proteases. These inhibitors may be used in vitro 
to prevent proteolysis which occurs in the process of 
production, isolation, purification, storage or transport 
of peptides and proteins. The inhibitors also contain a 
biotin moiety which can be recognized by avidin and 
avidin conjugates. The novel substituted isocoumarin 
and related heterocyclic compounds have the following 
structural formula: 
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(l) 
methionine, methionine sulfoxide, phenylalanine, tryp-
tophan, glycine, serine, threonine, cysteine, tyrosine, 
asparagine, glutamine, aspartic acid, glutamic acid, ly-
sine, arginine, histidine, phenylglycine, beta-alanine, 10t1n- pacer-T~ ~ 
~z 
y 
or a pharmaceutically acceptable salt, wherein 
S norleucine, norvaline, alpha-aminobutyric acid, ep-
silonaminocaproic acid, citrulline, hydroxyproline, or-
nithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-
piperidine carboxylic acdi), 0-methylserine, O-ethylse-
10 rine, S-methylcysteine, S-ethylcysteine, S-benzylcys-
teine, NH2-CH(CH2CHt2)-COOH, alpha-aminohep-
tanoic acid, NH2-CH(CH2-l-naphthyl)-COOH, 
NH2-CH(CH2-2-naphthyl)-COOH, NH2-CH(CH2-
cyclohexyl)-COOH, NH2-CH(CH2-cyclopentyl)-
COOH, NH2-CH(CH2-cyclobutyl)-COOH, 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1-6 fluorinated alkyl, C1-6 alkyl substituted 
with RI, C1-6fluorinated alkyl substituted with RI, C1-6 
alkoxy, C1-6 fluorinated alkoxy, C1-6 alkoxy substituted 
with RI, C1-6 fluorinated alkoxy substituted with RI, 15 C1-6 alkyl with a phenyl group attached to the alkyl 
group, C1-6 alkoxy with a phenyl group attached to the 
alkoxy group, C1-6 alkyl with an attached phenyl group 
substituted with R2, C1-6 alkyl with an attached phenyl 
group disubstituted with R2, C1-6 alkoxy with an at- 20 tached phenyl group substituted with R2, C1-6 alkoxy 
with an attached phenyl group disubstituted with R2, 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, or C1.6 alkyl-S-, 25 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialkyla-
mine, C1-6 alkyl-0-CO-, or C1-6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
wherein Spacer is any organic structure which is 30 
0-25 A long, 
wherein T represents -NH-, -0-, or -S-, and 
Y is selected from the group consisting ofH, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
Alternately the novel isocoumarin and related heter- 3S 
acyclic compound are represented by structure (I) 
where, 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1.6 fluorinated alkyl, C1-6 alkyl substituted 
with RI, C1-6 fluorinated alkyl substituted with rl, C1-6 40 
alkoxy, C1-6 fluorinated alkoxy, C1-6 alkoxy substituted 
with RI, C1-6 fluorinated alkoxy substituted with RI, 
C1-6 alkyl with a phenyl group attached to the alkyl 
group, C1-6 alkoxy with a phenyl group attached to the 
alkoxy group, C1-6 alkyl with an attached phenyl group 45 
substituted with R2, C1-6 alkyl with an attached phenyl 
group disubstituted with R2, C1-6 alkoxy with an at-
tached phenyl group substituted with R2, C1-6 alkoxy 
with an attached phenyl group disubstituted with R2, 
wherein R2 represents halogen, COOH, OH, CN, SO 
N02, NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, C1-6 
dialkylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialkyla- SS 
mine, C1-6 alkyl-0-CO-, or C1-6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
NH2-CH(CH2-cyclopropyl)-COOH, trifluoroleucine, 
or hexafluoroleucine, 
wherein T represents -NH-, -0-, or -S-, and 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
The compounds of Formula (I) can also contain one 
or more substituents at position B as shown in the fol-
lowing structure: 
B 0 
e;oo,~--T~ 0 
BWZ 
B y 
wherein electronegative substituents such as N02, 
Cn, Cl,COOR, and COOH will increase the reactivity 
of the isocoumarin, and electropositive substituents 
such as NH2, OH, alkoxy, thioalkyl, alkyl, alkylamino, 
and dialkylamino will increase its stability. Neutral sub-
stituents could also increase the stability of acyl enzyme 
and improve the effectiveness of the inhibitors. 
The complete structure of biotin in the biotin-Spacer 
moiety is shown below. 
0 
II 
.,.,.,........ 
HN NH 
II 
0 
Spacer 
Other substituted isocoumarins have been prepared 
earlier for other purposes (illustrative examples: 3-
chloroisocoumarin, Davies and Poole, J. Chem. Soc., 
pp 1616-1629(1928); 3-chloro and 3,4-
dichloroisocoumarin, Milevskaya, Belinskaya, and wherein Spacer represents -[NH-(CH2. )n-CO]n-, -[NH-(CHi)n-NH-CO]n-. -[N- Yagupol'skii, Zhur. Org. Khim. 9, pp 2145-2149(1973); 
H-C6H4-CO]n-. -[NH-C6ff4-NH-CO]n-. 60 3-methyl and 4-carboxy-3-methylisocoumarin, Tirod-
-NH-(CH2)n-CO-NH-(CH2)n-NH-CO-, kar and Usgaonkar, Ind. J. Chem. 7, pp 
-NH-(CH2)n-CO-NH-(CH2)3-NH-(CH2. 1114-1116(1969); 7-nitro and 7-aminoisocoumarin, )3-NH-CO-CH2CH2-CO-, or -(AA)n-. where Choksey and Usgaonkar, Ind. J. Chem. 14B, pp 596-598 
n= 1-6, · (1976), the preceding articles are incorporated herein by 
wherein AA is a side chain blocked or unblocked 65 reference). 
amino acid with the L configuration, D configuration, A number of other substituted isocoumarins have 
or no chirality at the a-carbon selected from the group been prepared recently for inhibition of serine proteases 
consisting of alanine, valine, leucine, isoleucine, praline, (3-chloroisocoumarin, Harper, Hemmi, and Powers, J. 
5 
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Am. Chem. Soc. 105, pp 6518-6520(1983); 3,4-
dichloroisocoumarin, Harper, Hemmi, and Powers, 
Biochemistry 24, pp 1831-1841 (1985); 3-alkoxy-7-
amino-4-chloroisocoumarin, Harper and Powers, J. 
Am. Chem. Soc 106, pp 7618-7619(1984), Harper and S 
Powers, Biochemistry 24, 7200-7213 (1983); substituted 
isocoumarins with basic groups (aminoalkoxy, 
guanidino or isothiureidoalkoxy), Kam, Fujikawa and 
Powers, Biochemistry 27, pp 2547-2557 (1988); 7-sub-
stituted 3-alkoxy-4-chloroisocoumarins, Powers, Kam, 10 
Narasimhan, Oleksyszyn, Hernandez and Ueda, J. Cell 
Biochem. 39, pp 33-46 (1989), Powers, Oleksyszyn, 
Narasimhan, Kam, Radhakrishnan and Meyer, Jr. Bio-
chemistry 29, 3108-3118 (1990), the preceding articles 
are incorporated herein by reference; Powers and Har- lS 
per, U.S. Pat. No. 4,596,822; Powers and Kam, U.S. Pat. 
No. 4,845,242; Powers, Kam, Oleksyszyn, Glinski, and 
Hernandez, U.S. Pat. No. 5,089,633; Powers and Kam, 
U.S. Pat. No. 5,089,634 which are also incorporated by 
reference). 20 
was retained on the avidin beads. This procedure allows 
removal of the protease from enzyme and zymogen 
mixture. In contrast to the Williams procedure, the use 
of biotinylated isocoumarins allows either an inacti-
vated serine protease to be formed or a reactivatable 
serine protease to be formed depending on the nature of 
the bond linking the spacer to the isocoumarin (chang-
ing this bond from an amide to a urea linkage changes 
the ratio of irreversible alkylation to reversible acyla-
tion). Thus, we have the option of obtaining active 
enzyme from the avidin column. This is not possible 
with the Williams procedure which uses an irreversible 
chloromethyl ketone inhibitor. 
Although little information is available on the struc-
ture of biotin binding site of avidin, the spacer between 
the biotin and the ligand molecule such as the isocouma-
rin, chloromethyl ketone or insulin is crucial for the 
binding of a biotinylated ligand to avidin. Green et al. 
(Biochem. J. 125, pp 781-791 (1971)) attempted to de-
termine the depth of the biotin binding site on avidin by 
studying the effect of chain length of cu-bis(biotinyldia-The following compounds are representative of the 
invention: 
7-biotinylamino-4-chloro-3-propyloxyisocoumarin 
7-biotinylamino-4-chloro-3-(2-phenylethoxy)isocouma-
rin 
7-( 6-biotinylaminocaproyl)amino-4-chloro-3-ethox-
yisocoumarin 
7-(6-biotinylaminocaproyl)amino-4-chloro-3-propylox-
yisocoumarin 
mines) on avidin polymer formation. They concluded 
that stable polymers were formed when the chaip link-
ing the carboxyl groups of the biotins was 18 A long 
25 and the carboxyl group must lie about 8-9 A beneath 
the surface of the avidin molecule. Finn et al. (Biochem-
istry 23, pp 2554-2558 (1984)) also calculated that the 
distance between the carboxyl group of dethiobiotin 
and the N-terminal amino group of the insulin B-chain 
30 would be 9.77 A for dethiobiotinyl-Al-insulin, 18.36 A 
for dethiobiotinyl-A2-insulin, and 25.52 A for dethiobi-
otinyl-A 1-DP A-insulin (Al, A2, and Al-DPA had dif-
ferent chain length of spacers). Thus, any of these li-
gands should have sufficient space between the dethi-
7-( 6-biotinylaminocaproyl)amino-4-chloro-3-(2-
pheny lethoxy )isocoumarin 
7-[6-(6-biotinylaminocaproyl)aminocaproyl)amino-4-
chloro-3-(2-phenylethoxy)isocoumarin 
7-[ 6-( 6-biotinylaminocaproyl)aminocaproyl)amino-4-
chloro-3-methoxyisocoumarin 
7-biotin-NH(CH2)2NH-COCH2NHCONH-4-chloro-
3-(2-phenylethoxy)isocoumarin 
35 obiotinyl and insulin portions to bind normally to avi-
din. However, only the longest of the three ligands 
showed the same rate of dissociation from Suc-avidin as 
dethiobiotin itself. Therefore, spacer arms are required It has been found that compounds of Formula (I) are 
effective inhibitors of the proteolytic function of human 
leukocyte elastase as shown in Table I. Compounds of 40 
Formula (I) are also effective inhibitors of the proteo-
lytic function of chymotrypsin and pancreatic elastase 
as shown in Table I. Compounds of Formula (I) are also 
effective in the prevention of unnecessary proteolysis 
caused by chymotrypsin and elastase in the process of 45 
purification, transport and storage of peptides and pro-
teins as shown in Table I by effective inhibition of chy-
motrypsin and elastase. 
Compounds of Formula (I) with a group consisting of 
biotinylamino with biotinylamino group attached to 50 
alkanoylamino, Y group of Cl, and Z group of phenyle-
thoxy group are effective in the inhibition of rat granule 
chymase as shown in Table II. The reactivation of in-
hibited PPE, chymotrypsin, or rat granule chymase by 
these biotin isocoumarins in the presence of hydroxy- SS 
]amine as shown in Table Ill, and IV is useful in the 
purification of these enzymes from enzyme mixtures or 
granules by applying the inhibited granules to the avidin 
beads, where the biotinylated enzymes form tight com-
plex with avidin and are retained on the column. Finally 60 
the enzyme can be reactivated and eluted off the col-
umn with a hydroxylamine solution. 
The tight complex of biotin-avidin has been used as a 
powerful tool for purifying proteins. One such example 
is Williams et al., J. Biol. Chem. 264, pp 7536-7545 6S 
(1989). A biotinylated+aminocaproyl-peptide chlo-
romethylketone was used to react with an active prote-
ase to form the biotinylated inactivated enzyme which 
for optimizing the interaction between the biotinylated 
ligand and the avidin complex, and longer spacers are 
preferred. 
The biotin-avidin interaction is very useful in many 
areas such as immunoassays, receptor studies, im-
munocytochemical staining and protein isolation. In the 
enzyme immunoassay system, the biotinylated antibody 
is bound to the immobilized antigen or primary anti-
body, and avidin can be conjugated with enzymes, 
fluorochromes, ferritin or colloidal markers. The biotin-
avidin interaction can also be used in blotting tech-
niques for detecting proteins. It is very useful in the 
staining of cellular antigenic determinants. A wide vari-
ety of biotinylated primary probes such as monoclonal 
antibodies, lectins, vitamins, sugars, hormones and lipo-
proteins have been used. This specific interaction has 
also been used successfully in the selective retrieval of 
labelled plasma membrane components (Orr, J. Biol. 
Chem. 256, pp 761-766 (1981)). Biotinylated proteins 
can be used as probes of protein structure and protein-
protein interaction (Billingsley et al. Biotechniques 5, 
pp 22-31 (1987)). 
Inactivation rates of serine proteases by substituted 
isocoumarins were measured by the incubation method. 
An aliquot of inhibitor (25 or 50 µ.l) in Me2SO was 
added to a buffered enzyme solution (0.01-2.3 µ.M) to 
initiate the inactivation. Aliquots (50-100 µ.l) were 
withdrawn at various intervals and the residual enzy-
matic activity was measured. Me2SO concentration in 
the reaction mixture was 8-12% (v/v). O.IM Hepes, 
7 
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0.5M NaCl, pH 7.5 buffer was utilized for the assays of et al., N. Eng. J. Med. 304, pp 192-196 (1981); Rinaldo, 
chymotrypsin, cathepsin G (cat G), porcine pancreatic ibid 301, 900-909 (1982)). 
elastase (PPE), human leukocyte elastase (HLE) and rat It is known that in vitro activity of elastase inhibitors 
granule serine proteases. O.lM Hepes, O.OlM CaCh, pH correlates with in vivo activity in animal models of 
7.5 buffer was utilized for the assays of trypsin and s emphysema and inflammation (Otterness et al., editor, 
human recombinant (HR) granzyme A. The inhibitor Advances in Inflammation Research, Vol. 11, Raven 
concentrations are shown in the Tables I and II. Peptide Press 1986, and this article is incorporated herein by 
nitroanilides with appropriate sequence were used as reference). Prophylactic administration of an inhibitor 
substrates for various serine proteases. All peptide 4- of elastase significantly diminishes the extent of elastase-
nitroanilide hydrolysis was measured at 410 nm 10 induced emphysema (Kleinerman et al., Am. Rev. 
(E410=8800M-lcm:....1; Erlanger et al., Arch. Biochem. Resir. Dis. 121, pp 381-387 (1980); Lucey et al., Eur. 
Biophys. 95, pp 271-278 (1961), incorporated herein by Respir. J. 2, pp 421-427 (1989)). Thus the novel inhibi-
reference). Peptide thioester hydrolysis rates were mea- tors described here should be useful for the treatment of 
sured with assay mixtures containing 4,4' -dithiodipyri- emphysema and inflammation. Elastase inhibitors have 
dine (E324=19800M-lcm-l; Grasetti & Murray, Arch. IS been used orally, by injection or by instillation in the 
Biochem. Biophys. 119, pp. 41-49 (1967), incorporated lungs in animal studies (Powers, Am. Rev. Respir. Dis., 
herein by reference). First order inactivation rate con- 127, s54-s58 (1983); Powers and Bengali, Am. Rev. 
stant Ckobs) were obtained from plots of In (v1/v0) vs Respir. Dis. 134, pp 1097-1100 (1986) and these two 
time, and the correlation coefficients were greater than articles are incorporated herein by reference). The in-
0.98. 20 hibitors described above can be used by any of these 
Table I shows the inactivation rate constants of chy- routes. 
motrypsin, cathepsin G (cat G), porcine pancreatic For treatment of inflammation, the compounds of 
elastase (PPE), human leukocyte elastase (HLE), tryp- Formula (I) may be administered orally, topically or 
sin and human recombinant (HR) granzyme A inhibited parenterally. The term parenteral as used includes sub-
by biotinylated isocoumarins. The compound with bio- 2S cutaneous injection, intravenous, intramuscular, intra-
tin-spacer-T group of 6-biotinylaminocaproylamino, Y sternal injection or infusion techniques. The dosage 
group of Cl and Z group of phenylethoxy is a good depends primarily on the specific formulation and on 
inhibitor for chymotrysin. The structures with biotin- the object of the therapy or prophylaxis. The amount of 
Spacer-T group of 6-biotinylaminocaproylamino, Y the individual doses as well as the administration is best 
group of Cl and Z group of propoxy, ethoxy or me- 30 determined by individually assessing the particular case. 
thoxy are the best inhibitors for HLE. These bi- The pharmaceutical compositions containing the ac-
otinylated isocoumarins which do not contain a positive tive ingredient may be in a form suitable for oral use, for 
charged group are poor inhibitors of trypsin and HR example as tablets, troches, lozenges, aqueous or oily 
granzyme (a trypsin-like enzyme). suspensions, dispersible powders or granules, emulsions, 
Table II shows the inhibition of rat granule chymase 3S hard or soft capsules or syrups or elixirs. Dosage levels 
and tryptase by biotinylated isocoumarin derivatives. of the order to 0.2 mg to 140 mg per kilogram of body 
The structure with biotin-spacer-T group of 6- weight per day are useful in the treatment of above-
biotinylaminocaproylamino, Y group of Cl and Z group indicated conditions (10 mg to 7 gms per patient per 
of phenylethoxy inactivated chymase instantly 50%, day). The amount of active ingredient" that may be com-
and also inhibited tryptase very slowly. Table III shows 40 bined with carrier materials to produce a single dosage 
the reactivation of inhibited PPE, chymotrypsin, tryp- form will vary depending upon the host treated and the 
sin and rat granule chymase by biotinylated isocouma- particular mode of administration. 
rins in buffer and in the presence of hydroxylamine. For injection, the therapeutic amount of the com-
Inhibited chymotrypsin regained 10-15% of enzyme pounds of Formula (I) or their pharmaceutically accept-
activity in the buffer after two days, but regained 100% 4S able salts will normally be in the dosage range from 0.2 
of activity in the presence of hydroxylamine. Inhibited to 140 mg/kg of body weight. Administration is made 
rat granule chymase regained 30-100% of activity in by intravenous, intramuscular or subscutaneous injec-
the presence of hydroxylamine. Table IV shows the tion. Accordingly, pharmaceutical compositions for 
effect of avidin and streptavidin on reactivation of in- parenteral administration will contain in a single dosage 
hibited PPE and chymotrypsin. Avidin does not show so form about 10 mg to 7 gms of compounds of Formula 
any effect, but streptavidin enchanced reactivation of (I) per dose. In addition to the active ingredient, these 
inhibited chymotrypsin and PPE about 10-20%. pharmaceutical compositions will usually contain a 
Pulmonary emphysema is a disease characterized by buffer, e.g. a phosphate buffer which keeps the pH in 
progressive loss of lung elasticity due to the destruction the range from 3.5 to 7 and also sodium chloride, manni-
of lung elastin and alveoli. The destructive changes of SS tol or sorbitol for adjusting the isotonic pressure. 
lung parentchyma associated with pulmonary emphy- A composition for topical application can be formu-
sema are caused by uncontrolled proteolysis in lung lated as an aqueous solution, lotion, jelly or an oily 
tissues (Janoff, Chest 83 pp 54-58 (1983)). A number of solution or suspention. A composition in the form of an 
proteases has been shown to induce emphysema in ani- aqueous solution is obtained by dissolving the com-
mals (Marco et al., Am. Rev. Respir. Dis. 104, pp 60 pounds of Formula (I) in aqueous buffer solution of pH 
595-598 (1971); Kaplan, J. Lab. Clin. Med. 82, pp 4 to 6.5 and if desired, adding a polymeric binder. An 
349-356 (1973)), particularly human leukocyte elastase oily formulation for topical application is obtained by 
(Janoff, ibid 115, pp 461-478 (1977)). Leukocyte elas- suspending the compounds of Formula (I) in an oil, 
tase and other mediators of inflammation also appear to optionally with the addition of a swelling agent such as 
play a role in diseases such as mucocutaneous lymph 6S aluminium stearate and/or a surfactant. 
node syndrome (Reiger et al., Eur. J. Pediatr. 140, pp To use the above inhibitors in vitro, they are dis-
92-97 (1983) and adult respiratory distress syndrome solved in an organic solvent such as dimethylsulfoxide 
(Stockley, Clinical Science 64, pp 119-126 (1983); Lee or ethanol, and are added to an aqueous solution con-
9 
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taining serine proteases. The final concentration of the 
organic solvent should be less than 25%. The inhibitors 
may also be added as solids or in suspension. The serine 
protease inhibitors of this invention would be useful in a 
variety of experimental procedures where proteolysis is 5 
a significant problem. Inclusion of these inhibitors in a 
radioimmunoassay experiments would result in higher 
sensitivity. The use of these inhibitors in plasma frac-
tionation procedures would result in higher yields of 
valuable plasma proteins and would make purification 10 
of the proteins easier. The inhibitors disclosed here 
could be used in cloning experiments utilizing bacterial 
cultures, yeast and purified cloned product in higher 
yield. 
The following examples are given to illustrate the 15 
invention and are not intended to limit it in any manner. 
EXAMPLE 1 
EXAMPLE 3 
Preparation of 
7-biotinylamino-4-chloro-3-propyloxyisocoumarin 
This compound was prepared similarly as 7-
biotinylamino-4-chloro-3-(2-phenylethoxy)isocoumarin 
from biotin acid chloride and 7-amino-4-chloro-3-
propyloxyisocoumarin, yield 20%, mp 127°-131' C., 
NMR was consistent with the assigned structure, mass 
spectra (FAB+) m/e=502(M+Na+1). Anal. Cale. for 
C22H26N30sCIS.H20: C, 53.06; H, 5.67; N, 8.44; Cl, 
7.12. Found: C, 53.30; H, 5.67; N, 8.49; Cl, 7.03. 
EXAMPLE4 
Preparation of 
7-[(6-biotinylamino)caproyl]amino-4-chloro-3-
propyloxyisocoumarin 
Preparation of 
7-(biotinylamino )-4-chloro-3-(2-phenylethox-
y )isocoumarin 
Biotin acid chloride was prepared by incubating 0.4 g 
(1.6 mmole) of biotin in 6 ml of thionyl chloride at 
25°-35° C. for 1 hr, and excess thionyl chloride was 25 
removed under vacuum. The acid chloride was used for 
the next step without further purification. Biotin acid 
chloride and 7-amino-4-chloro-3-(2-phenylethox-
y)isocoumarin (0.26 g, 0.8 mmole) was dissolved in 
small amount of DMF, and then Et3N (0.08 g, 0.08 30 
mmole) were added. The reaction mixture was stirred at 
This compound was prepared similarly as 7-[(6-
20 biotinylamino)caproyl]amino-4-chloro-3-(2-phenyle-
thoxy)isocoumarin from 6-(biotinylamino)caproic acid 
chloride and 7-amino-4-chloro-3-propyloxyisocouma-
rin, yield 25%, mp 141-145° C., NMR was consistent 
with the assigned structure, mass spectra (F AB+) 
m/e=593(M+1). Anal. Cale. for C2sH37N406ClS.0.5-
r. t. overnight. The product was purified by column 
chromatography, yield 34%, mp 182'-185' C.; TLC, 
Rp0.25(CH2C!i:MeOH=15:1), NMR was consistent 
with the assigned structure, mass spectra (FAB+) 35 
m/e=542(M+1). Anal. Cale for C21H2sN30sCIS 0.25 
H20: C, 59.39; H, 5.22, N, 7.70. Found: C, 59.08; H, 
5.37; N, 7.94. 
7-(Biotinylamino )-4-chloro-3-(pentafluoropropox-
y )isocoumarin can be prepared by the same procedure. 40 
EXAMPLE2 
Preparation of 
H20: C, 55.14; H, 6.13; N, 9.53; Cl, 6.04. Found: C, 
54.81; H, 6.26; N, 9.47; Cl, 5.93. 
EXAMPLES 
Preparation of 7-[(6-biotinylamino)caproyl]amino-4-
chloro-3-ethoxyisocoumarin. 
This compound was prepared similarly as 7-[(6-
biotinylamino )caproyl]amino-4-chloro-3-(2-pheny le-
thoxy )isocoumarin from 6-(biotinylamino)caproic acid 
chloride and 7-amino-4-chloro-3-ethoxyisocoumarin, 
yield 15%, mp 156°-162' C., NMR was consistent with 
the assigned structure, mass spectra (FAB+) m/e=601 
(M+Na+ 1). Anal. Cale. for C27H35N406ClS.H20: C, 
55.03; H, 6.43; N, 9.17; Cl, 5.80. Found: C, 54.81; H, 
6.26; N, 9.23; Cl, 5.69. 
EXAMPLE6 
Preparation of 7-[ ( 6-biotiny I amino )caproyl]amino-4-chloro-3-(2-
phenylethoxy )isocoumarin 45 7-[6-(6-piotinylaminocaproyl)aminocaproyl]amino-4-
6-(Biotinylamino)caproic acid was prepared from chloro-3-(2-phenylethoxy)isocoumarin. 
N-hydroxysuccinimido biotinate (Jasiewicz et al., Exp. 6-(6·Biotinylaminocaproyl)aminocaproic acid was 
Cell Res. 100, PP 213-217 (1976)) and 6-aminocaproic prepared from the reaction of 6-biotinylaminocaproic 
acid methyl ester hydrochloride by a previously de- acid and l,l'-carbonyldiimidazole (CDI) with 6-
scribed method (Hofmann et al., Biochemistry 23, pp 50 
2547-2553 (1984)). 6-(Biotinylamino)caproic acid chlo- aminocaproic acid methyl ester, subsequent alkaline 
ride was prepared by incubating 6-(biotinylamino)ca- hydrolysis of the corresponding methyl ester, and acidi-
proic acid (0.36 g, 1 mmole) in 4 ml of thionyl chloride fication. 6-(6-Biotinylaminocaproyl)aminocaproic acid 
at 25•_35• C. for 1 h, and excess thionyl chloride was (0.5 g, 1.1 mmole) was dissolved in 15 ml ofDMF at 70° 
removed under reduced pressure. The residue was dis- 55 C. and cooled to 40° C., then 7-amino-4-chloro-3-(2-
solved in DMF and 7-amino-4-chloro-3-(2-phenyle- phenylethoxy)isocoumarin (0.4 g, 1.3 mmole) was 
thoxy)isocoumarin (0.34 g, I mmole) and Et3N (0.1g,1 added, followed by the addition of 1-hydroxybenzo-
mmole) were added and the reaction mixture was triazole (HOBt, 0.172 g, 1.3 mmole) and diisopropylcar-
stirred at r.t. overnight. The product was purified from bodiimide (0.16 g, 1.3 mmole). The mixtures were 
column chromatography and eluted with 60 stirred at r.t. overnight, and the solvent was evaporated. 
CH2C!i:MeOH=lO:l, yield, 28%, mp 163'-167" C., The crude product was purified on a silica gel column 
NMR was consistent with the assigned structure, mass which was eluted with CHCl3:MeOH:HOAc=65:10:3. 
spectra (FAB+) m/e=655 (M+ 1). Anal. Cale. for The eluted product contained HOBt which was then 
C33H39N406ClS.H20: C, 58.81; H, 6.14; N, 8.32; Cl, removed by washing with IN HCI several times. The 
5.27. Found: C, 58.72; H, 6.22; N, 8.90; Cl, 5.50. 6S final product was obtained as a yellow solid, yield 33%, 
7-[(6-Biotinylamino)caproyl]amino-4-chloro-3-(pen- mp 163'-165' C., NMR was consistent with the as-
tafluoropropoxy)isocoumarin can be prepared by the signed structure, mass spectra (FAB+) m/e=768 
same procedure. (M+ 1). Anal. Cale. for C39HsoNs07CIS: C, 60.96; H, 
11 
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6.56; N, 9.11; Cl, 4.60. Found: C, 60.72; H, 6.6; N, 9.04; 
Cl, 4.67. 
EXAMPLE7 
NMR was consistent with the assigned structure, mass 
spectra (FAB+) m/e=444.5 (M+ 1). Deblocking the 
Boe group from biotin-NH(CH2)2NH-COCH2NH-
Boc with trifuoroacetic acid at o• C. and addition of 
Preparation of 5 saturated HCI in ethyl acetate to the residue gave the 
7-[6-( 6-biotinylaminocaproyl)aminocaproyl]amino-4- product, yield 81 %, TLC: Rp0.32 (butanol:acetic 
chloro-3-methoxyisocoumarin. acid:H20=4:1:1), mp 146°-148° C., NMR was consis-
6-(6-Biotinylaminocaproyl)aminocaproic acid was tent with the assigned structure. 
prepared by the same procedure as described in Exam- 7-Biotin-NH-(CH2)2NH-COCH2NHCONH-4~ 
pie 6. 6-(6-Biotinylaminocaproyl)aminocaproic acid 10 chloro-3-(2-phenylethoxy)isocoumarin was synthesized 
(0.65 g, 1.4 mmole) was dissolved in 15 ml of DMF at from the reaction of 7-amino-4-chloro-3-(2-phenyle-
700 C. and cooled to 40• c., then 7-amino-4-chloro-3- thoxy)isocoumarin and biotin-
methoxyisocoumarin (0.37 g, 1.7 mmole) was added, NH(CH2)2NH-COCH2NH.HCI. After the isocouma-
followed by the addition of HOBt (0.22 g, 1.7 mmole) rin (0.43 g, 1.35 mmole) and CDI (0.24 g, 1.48 mmole) 
and 1,3-dicyclohexylcarbodiimide (DCC, 0.34 g, 1. 7 15 were dissolved in 8 ml ofDMF at 0° C. and stirred at r.t. 
mmole). The mixtures were stirred at r. t. overnight, for 4 h, the solution of biotinylated derivative (0.47 g, 
and the solvent was evaporated. The crude product was 1.23 mmole) and triethylamine (0.17 ml, 1.23 mmole) in 
purified on a silica gel column which was eluted with DMF was added. The reaction mixture was stirred at 
CHCh:MeOH:HOAc=65:10:2. The eluted product r.t. for 24 h, then decolorized, filtered, and evaporated 
contained HOBt which was removed by washing with 20 to. give dark greenish residue. The residue was washed 
lN HCI several times. The final product was identified with water and 0.5N HCI, and then applied on a silica 
by NMR and mass spectra (FAB+) m/e=677 (M+). gel column which was eluted with CHCIJ:MeOH (5:1). 
The final product was obtained as · yellowish green 
EXAMPLE 8 solid, yield 13%, TLC: Rp0.46 (CHCl3:MeOH=5:1), 
Preparation of 25 mp 192°-193° C. (dee), NMR was consistent with the 
7-biotin-NH-(CH2)2NH-COCHiNHCONH-4-chloro-3- assigned structure, mass spectra (FAB+) m/e=686 (2-phenylethoxy)isocoumarin. (M+ 1). Anal. Cale. for C32H37N601CIS: C, 56.09; H, 
5.44; N, 12.27. Found: C, 55.92; H, 5.46; N, 12.15. 
EXAMPLE9 
Biotinylethylenediamine.HCI. Biotin (1 g, 4.1 mmole) 
was dissolved in 20 ml of DMF at 70° C. and cooled to 30 
40° C., 1,1'-carbonyl diimidazole (0.97 g, 6 mmole) in 3 I fD Elution of inhibited PPE by 
m o . MF was then added and white precipitates were 7-[6-( 6-biotinylaminocaproyl)aminocaproyl]amino-4-
appeared. After stirring at r. t. for two hours, ethylene- chloro-3-methoxyisocoumarin from avidin-agarose 
diamine (1.34 ml, 20 mmole) in 10 ml of DMF was column with NHiOH. 
added and stirred for another 3 hours. After DMF was 35 
evaporated, the semisolid residue was dissolved in 50 ml PPE (1 mg, 0.04 mmole) was inhibited by bi-
of refluxed methanol and the unreacted biotin was re- otinylated isocoumarin (0.5 mmole) in O.lM Hepes, 
moved by filtration. After the solution was evaporated 0.5!"f NaCl, pH 7.5 buffer at 25° C. for 10 min, 7% of 
to dryness, the residue was washed with CHCI3 to re- residual enzyme activity was found. Excess of inhibitors 
move the imidazole, dissolved in 6 ml of water, acidified 40 ~as removed by Seph~dex G-25 column and the inhib-
to pH 3.0 with lN HCI, and evaporated to dryness. The 1ted PPB was eluted with O.lM acetate, 0.5M NaCl, pH 
pr?<luct was crystallized from methanol to give 1.04 g ?·O buffer and had. 16% of enzyme a~tivity. This i~h!b-
(y1eld 79%), TLC: Rp0.21 (butanol:acetic acid:- 1ted enzyme solution was then apphed on the av1dm-
H20=4:1:1), mp 241°-242° C., NMR is consistent with agarose column and 34% of protein went through (mea-
the structure. 45 sured by optical density at 280 nm). The column was Biotin-NH(CH2)2NH-COCH2NH.HCI. Biotin- washed with pH 5.0 acetate buffer, then eluted with 
NH(CH2)2NH-COCH2NH-Boc was prepared from 0.lM Hepes, 0.5M NaCl, and 0.5M NH20H, pH 7.5 
the reaction ofbiotinylethylenediamine.HCI, DCC and buffer and 37% of protein was eluted out (measured by 
t-butyloxycarbonylglycine (Boc-Gly) in the presence of OD2so) from the column. In these protein fractions, 
triethylamine in DMF, yield 53%, TLC: Rp0.55 40% of PPB activity was detected. 
(butanol:acetic acid:H20=4:1:1), mp 136°-139° C., 
TABLE I 
Inhibition of Serine Proteases bx Biotin-lsocoumarin Derivatives•. 
~!!'.[I] (M-ls-ll 
Compounds Chymotrypsinb Cat. QC HLEd PPE' Trypsinf HR Granyzme Ag 
7-biotinylamino-4-chloro- 330 Nlh 740 NI 1.1 
3-(2-phenylethoxy)isocoumarin (1) 16S 
7-biotinylamino-4-chloro- 6S 6.7 19,900 470 2.2 
3-propoxyisocoumarin (2) 
7-(6-biotinylaminocaproyl)amino-4-chloro- 1,080 13%; 670 NI 1.0 NI 
3-(2-phenylethoxy)isocoumarin (3) 190 
7-(6-biotinylaminocaproyl)amino- 260 3.3 76,700 350 10.6 NI 
4-chloro-3-propoxyisocoumarin (4) 
7-(6-biotinylaminocaproyl)amino- 260 S9 96,000 S20 16.6 26%; 
4-chloro-3-ethoxyi~oumarin {S) 
7-[ 6-( 6-biotinylaminocaproyl)aminocaproy l]- 2.2 37,SOO So/c; 
amino-4-chloro-3-methoxyisocoumarin (6) 
7-[ 6-( 6-biotinylaminocaproyl)aminocaproyl]- NI 230 NI 
amino-4-chloro-3-(2-phenylethoxy)-
isocoumarin (7) 
7"biotin-NH(CH2)2NH-COCH2NHCONH- 640 19%; 6.6 18o/ci 
13 
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TABLE I-continued 
Inhibition of Serine Proteases by Biotin-Isocoumarin Derivatives•. 
C-Ompounds Chyrnotrypsinb Cat. Q< HLEd PPE' Trypsinf HR Granyzme Ag 
4-<:hloro-3-(2-phenylethoxy)isocoumarin (8) 100 
"Inhibition"'"' meuured in 0.1MHopes,0.S M NaCl (or O.oJ M CaCli), pH 7.S buffer, S-10% MqSO and at 2s• C. Sue-Val-Pro-NA (0.48 mM) was 
med• the 111bstrate for ch)'lllOlryplin and cat G. MeO-Suc-Ala-Ala-Pro-Val-NA (0.24-0.47 mM) and Sue-Ala-Ala-Ala-NA (0.29--0.48 mM) were U5Cd 
•the wbotrate for HLE and PPE reopeaively. Z-Olu-Phe-Arg-NA (0.032 mM) was a subottate for trypoin. Z-Arg-SBzl (0.120 mM) was a substrate 
for human recombinant (HR) panzyme A. 
~or CODCeDttations were 20--400 ,..M. 
'Inhibitor concentrations were 7S-.OO ,..M. 
"Inhibitor coecentrations were t.f>-210 ,..M. 
"Inhibitor concntrations were 38-78 ,..M. 
lmhibitor conceattations -.e 41-42 ,..M. 
'Inhibitor CODCeDttations were 160-210 ,..M. 
'10 inhibition after JO min of incubation of inhibitor and enzyme. 
it'm:entage of inhibition after 10 min of incubetion of inhibitor and enzyme. 
TABLE II 
Inhibition of Rat granule Serine Proteases by Biotin-Isocoumarin Derivatives•. 
[I] Rat Granule Chyrnase Rat Granule Tryptase 
C-Ompounds {mM) % of inhibitionb ko;,,![I] (M-ls-1) 
7-{6-Biotinylaminocaproyl)amino-4-<:hloro-
3-(2-phenylethoxy)isocoumarin 
7-Biotinylamino-4-<:hloro-
3-(2-phenylethoxy)isocoumarin 
0.078 
0.2 
30-SO 6-12 
10-20 2-3 
"Inhibition was measured in 0.1 M Hopes. 0.S M NaCl, pH 7.S buffer, 10% Me2SO and at 2s• C. Suc-Phe-Leu-Phe-SBzl (0.14 
mM) Z-Gly-Arg-SBzl (0.06 mM) were used to measure chymase and tryptase activity respectively. 
6lnhibition was not time dependent. 
TABLE III 
Reactivation of Inhibited PPE, Chymotrypsin and Rat Granule Chymase 
by Biotin-Isocoumarins in Buffer and in the Presence of NH20H0 . 
% of Enzyme Activity Reactivated 
PPE 
__ C""h"'y'-'m=o.:.:try...,.P"'Si"'n __ Trypsin 
Inhibitor in bufferb +NH20H in bufferb +NH20H in bufferb 
7-biotinylamino-4-<:hloro-3-(2-phenyl- 15% 100% 
ethoxyisocoumarin {I) 
7-(6-biotinylaminocaproyl)amino- 10% 100% 
4-chloro-3-(2-phenylethoxy)-
isocoumarin (3) 
7-biotinylamino-4-<:hloro-3-propoxy- 35% 98% 
isocoumarin (2) 
7-(6-biotinylaminocaproyl)amino- 37% 90% 33% 
4-<:hloro-3-propoxyisocoumarin { 4) 
7-(6-biotinylaminocaproyl)amino- 66% 93% 92% 
4-chloro-3-ethoxyisocoumarin (5) 
Rat granule 
chymase 
+NH20H 
100% 
30-50% 
"Inhibition wuperformedatO.I M Hopes, 0.S M NaCl, pH 7.S buffer, 10% Me2SOand2s• C. Reactivation was carried out in the presence 
of 0.4 M of NH;PH, and occurred immediately after the addition of NH20H. 
"Enzyme activity was meuured after removal of e1cess inhibitor by centrifugation at o• C. with ccntricon· l 0 microconcentrator and 
ataying at 2s• C. for two days. 
TABLE IV 
Effect of Streptavidin and Avidin on Reactivation of inhibited Chymotrypsin and PPE". 
7-{6-biotinylaminocaproyl)amino-
4-chloro-3-(2-phenylethoxy)IC (3) 
7-biotinylamino-4-chloro-
3-(2-phenylethoxy)IC {I) 
7-(6-biotinylaminocaproyl)amino-
4-<:hloro-3-propyloxyIC (4) 
7-biotinylamino-4-chloro-
4-<:hloro-3-propyloxylC (2) 
Buffer 
15% 
10% 
% of Regained Enzl:'.!!!e Activitl:'. 
Chl:'.!!!ot~in PPE 
+ Streptavidin +Avidin Buffer + Streptavidin 
39% 12% 
27% 10% 
37% 43% 
35% 51% 
+Avidin 
32% 
32% 
"Percen1&1e of repined enzymatic activity was measured in 0.1 M Hopes, 0.S M NaCl, pH 7.S buffer, 8'i'C Me2SO and at 25• C. Excess 
inhibitor was removed from enzyme-inhibitor 'mixture by centrifugation twice with Amicon microconcentrator-10. Then 3-t units of 
avidin or strepavidin wu added and enzymatic activity was monitored for two days. 
What is claimed is: 
1. A compound of the formula: 
5,306,824 
16 15 
0 0 
s II II ~T-Spacer·Tw~ 0 
HN NH AflP ,,,P z 5 
'c ..... 
II y 
0 
or a pharmaceutically acceptable salt thereof, wherein 10 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1-6 fluorinated alkyl, C1.6 alkyl substi-
tuted with RI, C1.6 fluorinated alkyl substituted 
with RI, C1.6 alkoxy, C1-6 fluorinated alkoxy, C1-6 
alkoxy substituted with RI, C1.6 fluorinated alkoxy 15 
substituted with R 1, C1-6 alkyl with a phenyl group 
attached to the alkyl group, C1.6 alkoxy with a 
phenyl group attached to the alkoxy group, C1.6 
alkyl with an attached phenyl group substituted 
with R2, C1-6 alkyl with an attached phenyl group 20 
disubstituted with R2, C1.6alkoxy with an attached 
phenyl group substituted with R2, C1-6alkoxy with 
an attached phenyl group disubstituted with R2, 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1.6 alkyl, Ct-6 alkoxy, Ct-6 alkylamine, 25 
Ct-6 dialkylamine, Ct-6 alkyl-0-CO-, Ct-6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1.6alkoxy, C1-6.alkylamine, C1-6dialk-
ylamine, C1.6 alkyl-0-CO-, C1-6 alkyl- 30 
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
wherein Spacer is an organic structure which is 3-24 
A long and including a backbone comprising at 
least one of the members of the group consisting of 
-CH2-CH2-, -CO-NH-, -NH-CO-, 35 
-CH2-CO-, -CH2-NH-, -NH-CH2-, 
and-C6H4-, 
wherein T represents -NH-, -0-, or -S-, · 
Y is selected from the group consisting of H, halogen 
trifluoromethyl, methyl, OH and methoxy. 40 
2. A compound of the formula: 
0 0 
s II II . ~Spacer·Tw~ 0 
HN NH AflP ,,,P Z 
'c ..... 
II y 
45 
0 50 
or a pharmaceutically acceptable salt thereof, wherein 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, C1.6 fluorinated alkyl, C1-6 alkyl substi-
tuted with RI, C1-6 fluorinated alkyl substituted 55 
with RICt-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 
alkoxy substituted with RI, C1-6 fluorinated alkoxy 
substituted with RI, C1.6alkyl with a phenyl group 
attached to the alkyl group, C1-6 alkoxy with a 
phenyl group attached to the alkoxy group, C1-6 60 
alkyl with an attached phenyl group substituted 
with R2, C1.6 alkyl with an attached phenyl group 
disubstituted with R2, C1-6alkoxy with an attached 
phenyl group substituted· with R2, C1-6 alkoxy 
woith an attached phenyl group disubstituted with 65 
R2, 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1-6 alkyl, C1.6 alkoxy, C1-6 alkylamine, 
Ct-6 dialkylamine, Ct-6 alkyl-0-CO-Ct-6 alkyl-
0-CO-NH-, or Ct-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1.6alkoxy, C1-6alkylamine, Ct-6dialk-
ylamine, Ct-6 alkyl-0-CO-, C1.6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
spacer represents -[NH-(CH2)n-CO]n-. -[N-
H-(CH2)n-NH-CO]n-. -(NH-C6-
ff4-CO)n-. -(NH-C6B4-NH-CO)n-. -N-
H-(CH2)n-CO-NH-(CH2)n-NH-CO-, 
-NH-(CH2)n-CO-NH-(CH2)3-N-
H-(CH2)3-NH-CO-CH2CH2-CO-, 
wherein n= 1-6, 
wherein T represents -NH-, -0-, or -S-, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
3. A compound of the formula: 
0 
s w~RTW11 
N II I . 0 
H 0 
n ,,,P # Z 
HN...._ ,..NH y 
c 
II 
0 
or a pharmaceutically acceptable salt thereof, wherein 
Z is selected from the group consisting of H, halogen, 
C1-6 alkyl, Ct-6 fluorinated alkyl, C1-6 alkyl substi-
tuted with RI, C1.6 fluorinated alkyl substituted 
with RI, Ct-6 alkoxy, C1.6 fluorinated alkoxy, C1.6 
alkoxy substituted with R 1, C1.6 fluorinated alkoxy 
substituted with R 1, C1-6 alkyl with a phenyl group 
attached to the alkyl group, C1-6 alkoxy with a 
phenyl group attached to the alkoxy group, C1-6 
alkyl with an attached phenyl group substituted 
with R2, C1.6 alkyl with an attached phenyl group 
disubstituted with R2, C1.6alkoxy with an attached 
phenyl group substituted with R2, C1.6 alkoxy 
woith an attached phenyl group disubstituted with 
R2, 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1.6 alkyl, C1.6 alkoxy, C1.6 alkylamine, 
C1-6 dialkylamine, C1-6 alkyl-0-CO-, C1.6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1..t;alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, C1-6 alkyl-0-CO-, C1.6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tosylamino, 
wherein R is the side chain of a side chain blocked or 
unblocked amino acid residue selected from the 
group consisting of alanine, valine, leucine, isoleu-
cine, proline, methionine, methionine sulfoxide, 
phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, as-
partic acid, glutamic acid, lysine, arginine, histi-
dine, phenylglycine, beta-alanine, norleucine, nor-
valine, alpha-aminobutyric acid, epsilon-aminoca-
proic acid, citrulline, hydroxyproline, ornithine, 
homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid 
(2-piperidine carboxylic acid), 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, 
S-benzylcysteine, NH2-CH(CH2CHEt2. 
)-COOH, alpha-aminoheptanoic acid, 
NH2-CH(CH2-l-naphthyl)-COOH, 
17 
NH2-CH(CH2-2-naphthyl)-COOH, 
NH2-CH(CH2-cyclohexyl)-COOH, 
NH2-CH(CH2-cyclopentyl)-COOH, 
NH2-CH(CH2-cyclobutyl)-COOH, 
5,306,824 
18 
NH2-CH(CH2-cyclopropyl)-COOH, 
fluoroleucine, and hexafluoroleucine, 
wherein n= 1-6, 
wherein T represents -NH-, -0-, or -S-, 
tri-
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
4. A compound of the formula: 
0 
0 T II 
s If /WO ( y---"(AA)n I 
>--<. # # z 
HN...._ ,,,.NH Y 
c 
II 
0 
or a pharmaceutically acceptable salt thereof, wherein 
5 
10 
15 
20 
25 
Z is selected from the group consisting ofH, halogen, 30 
C1-6 alkyl, C1-6 fluorinated alkyl, C1-6 alkyl substi-
tuted with RI, C1-6 fluorinated alkyl substituted 
with RI, C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 
alkoxy substituted with RI, C1-6 fluorinated alkoxy 35 
substituted with RI, C1-6alkyl with a phenyl group 
attached to the alkyl group, C1-6 alkoxy with a 
phenyl group attached to the alkoxy group, C1-6 
alkyl with an attached phenyl group substituted 40 
with R2, C1-6 alkyl with an attached phenyl group 
disubstituted with R2, C1-6alkoxy with an attached 
phenyl group substituted with R2, C1-6 alkoxy 45 
woith an attached phenyl group disubstituted with 
R2, 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkyl, C1-6alkoxy, C1-6alkylamine, 50 
C1-6 dialkylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
55 
N02, NH2, C1-6 alkoxy, C1-6 alkylamine, C1-6 dialk-
ylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, C1-6 alkyl-S-, or tqsylamino, 
AA is a side chain blocked or unblocked amino acid 60 
residue, 
wherein n= 1-6, 
wherein T represents -NH...:...., -0-, or -S-, 
Y is selected from the group consisting of H, halogen, 65 
trifluoromethyl, methyl, OH and methoxy. 
5. A compound of the formula: 
0 
II 
c 
HN/ 'NH 
~T w 
s ~ Y'T~ ~z 
y 
or a pharmaceutically acceptable salt thereof, wherein 
Z is selected from the group consisting ofH, halogen, 
C1-6 alkyl, C1-6 fluorinated alkyl, C1-6 alkyl substi-
tuted with R', C1-6 fluorinated alkyl substituted 
with RI, C1-6 alkoxy, C1-6 fluorinated alkoxy, C1-6 
alkoxy substituted with R 1, C1-6 fluorinated alkoxy 
substituted with RI, C1-6alkyl with a phenyl group 
attached to the alkyl group, C1-6 alkoxy with a 
phenyl ~roup attached to the alkoxy group, C1-6 
alkyl with an attached phenyl group substituted 
with R2, C1-6 alkyl with an attached phenyl group 
disubstituted with R2, C1-6alkoxy with an attached 
phenyl group·substituted with R2, C1-6alkox~ with 
an attached phenyl group substituted with R , C1-6 
alkoxy with an attached phenyl group disubstituted 
with R2, . 
wherein R2 represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkyl, Ct-6alkoxy, C1-6alkylamine, 
C1-6 dialkylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-
0-CO-NH-, or C1-6 alkyl-S-, 
wherein RI represents halogen, COOH, OH, CN, 
N02, NH2, C1-6alkoxy, C1-6alkylamine, C1-6dialk-
ylamine, C1-6 alkyl-0-CO-, or C1-6 alkyl-
0-CO-NH-, Ct-6 alkyl-S-, or tosylamino, 
wherein T represents -NH-, -0-, or -S-, 
Y is selected from the group consisting of H, halogen, 
trifluoromethyl, methyl, OH and methoxy. 
6. A compound of the formula: 
0 0 
s II II ~Spaccr-NHW"' 0 
HN NH # #z 
'c,,,. 
11 o 
0 
or a pharmaceutically acceptable salt thereof, wherein 
Z 1s selected from the group consisting of methoxy, 
ethoxy, propyloxy, or phenylethoxy, 
wherein S{'acer is selected from the group consisting 
of -[NH-(CH2)6-CO]-, -[NH-(CH2. 
)6-C0]2-, or -[NH-(CH2h-NH-CO-CH-
2-NH-CO]-. 
7. A compound of the formula: 
0 
II 
c 
HN/ 'NH 
H H w (~Nw 
s ~ I o 
# # z 
Cl 
Z is selected from the group consisting of rnethoxy, 
ethoxy, propyloxy, or phenylethoxy. 
* * * * * 
